• Publications
  • Influence
Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited
BACKGROUND Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART). WeExpand
Leveraging Rapid Community-Based HIV Testing Campaigns for Non-Communicable Diseases in Rural Uganda
An integrated campaign engaging 74% of adult residents of a rural Ugandan parish identified a high burden of undiagnosed HIV, hypertension and diabetes, and demonstrates the feasibility of integrating hypertension, diabetes and communicable diseases into HIV initiatives. Expand
Polymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan Children
The prevalence of K13-propeller and FP2 polymorphisms did not increase over time, and was not associated with either time since prior receipt of an ACT or the persistence of parasites ≥2 days following treatment with an ACT, indicating that artemisinin resistance is not prevalent in Uganda. Expand
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy.
Significant CM-associated mortality persists, despite the administration of amphotericin B and HIV therapy, because of the high mortality rate before receipt of HAART and because of immune reconstitution inflammatory syndrome-related complications after HAART initiation. Expand
Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy
The data suggest that viral failure occurring 6 months or more after the start of ART regimens commonly used in Uganda is likely to be associated with NNRTI- and 3TC-resistant virus. Expand
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial
DP was superior to AL for reducing the risk of recurrent parasitemia and gametocytemia, and provided improved hemoglobin recovery, and appears to be a good alternative to AL as first-line treatment of uncomplicated malaria in Uganda. Expand
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in Uganda
Dihydroartemisinin-piperaquine is highly efficacious, and operationally preferable to AL because of a less intensive dosing schedule and requirements and should be considered for a role in the antimalarial treatment policy of Uganda. Expand
Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda.
In evaluations of known polymorphisms in parasites from patients with uncomplicated malaria in Kampala, Uganda, the presence of 8 pfcrt mutations and 2 pfmdr-1 mutations did not correlate with clinical response to therapy with chloroquine, suggesting that other factors may contribute to clinical outcomes. Expand
Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts.
There is no convincing evidence that the burden of malaria has decreased in Uganda in recent years, and major challenges to malaria control include very high malaria transmission intensity, inadequate health care resources, a weak health system, inadequate understanding of malaria epidemiology and the impact of control interventions, and inadequate epidemic preparedness and response. Expand
Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial
The effectiveness of a seven day course of quinine for the treatment of uncomplicated malaria in Ugandan children was significantly lower than that of artemether-lumefantrine, and these findings question the advisability of the recommendation forQuinine therapy for uncomplication malaria in Africa. Expand